Characterization of plantar verrucae among individuals with human immunodeficiency virus

1998 ◽  
Vol 88 (9) ◽  
pp. 442-445 ◽  
Author(s):  
R Meberg ◽  
E Kenyon ◽  
R Bierman ◽  
L Loveland ◽  
P Barbosa
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
Pilot Study ◽  
Hpv Infection ◽  
Hiv Patients ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

Plantar verrucae, caused by human papillomavirus (HPV), are commonly found in patients who have tested positive for the antibodies to human immunodeficiency virus (HIV). A better understanding of the characteristics of plantar verrucae in HIV+ patients in needed. A pilot study was conducted concentrating on three characteristics--the size, the number, and the clinical type--of verrucae present in this population. These parameters were studied in HIV+ and HIV- populations, and they were evaluated in relation to the CD4 levels of HIV+ individuals. The HIV+ individuals presented with plantar verrucae that were larger and more numerous than those found in HIV- individuals. The HIV+ population presented with all three clinical types of plantar verrucae and had significantly more mosaic-type warts than did HIV- individuals. The three characteristics did not correlate with CD4 cell counts, suggesting that the severity and extent of HPV infection do not depend on the level of immunosuppression of the HIV+ patient.

scholarly journals Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.

1996 ◽  
Vol 40 (11) ◽  
pp. 2664-2668 ◽  
Author(s):  
A M Been-Tiktak ◽  
I Williams ◽  
H M Vrehen ◽  
J Richens ◽  
D Aldam ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Transcriptase Inhibitor ◽  
Viral Loads ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Reverse Transcriptase Inhibitor ◽  
Cd4 Cell ◽  
Hiv 1

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

scholarly journals Acyclovir Use and Survival Among Human Immunodeficiency Virus‐Infected Patients with CD4 Cell Counts of < 500/mm

1998 ◽  
Vol 26 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Ramón A. Torres ◽  
James D. Neaton ◽  
Deborah N. Wentworth ◽  
Michael R. Barr ◽  
Donald Abrams ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Counts ◽  
Cd4 Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

Plantar Verrucae in Patients with Human Immunodeficiency Virus

2001 ◽  
Vol 91 (2) ◽  
pp. 79-84 ◽  
Author(s):  
Jeffrey M. Whitaker ◽  
Geoffrey L. Gaggero ◽  
Lacey Loveland ◽  
Lolita Segura ◽  
Peter Barbosa
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pilot Study ◽  
Treatment Response ◽  
Sample Population ◽  
Hiv Patients ◽  
Multicenter Studies ◽  
Immunodeficiency Virus

Several previous studies have yielded data showing that plantar and other cutaneous verrucae follow a more aggressive course in patients infected with human immunodeficiency virus (HIV) than in uninfected individuals. A pilot study was undertaken to identify trends in a sample population that would support this characterization of plantar verrucae in HIV+ patients and to determine whether there are differences in treatment response between HIV+ and HIV− patients. The results show that the HIV+ patients in the study presented with a significantly greater number and total area of lesions than did the HIV− patients. Furthermore, the HIV+ patients experienced a greater frequency of recurrence of their lesions following treatment with surgical curettage. These findings should provide the foundation for other extensive, multicenter studies to further characterize the treatment response of these lesions in HIV+ patients and to develop effective guidelines for their management. (J Am Podiatr Med Assoc 91(2): 79-84, 2001)

Sign in / Sign up

Export Citation Format

Share Document